Kakhi Sara, Soomro G Mustafa
Solent NHS Foundation Trust, Southampton, UK.
BMJ Clin Evid. 2015 Jun 3;2015:1019.
Obsessions or compulsions that cause personal distress or social dysfunction have been reported to affect about 3% of children and adolescents. In children, the disorder often presents at around 10 years of age. It persists in about 40% of children and adolescents at mean follow-up of 5.7 years. The disorder is disabling with adverse impact on functioning, including education and social/family life.
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of maintenance drug treatment for obsessive compulsive disorder in children and adolescents? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Two studies were included that addressed the question of maintenance drug treatment for Obsessive Compulsive Disorder (OCD) in children and adolescents.
In this systematic review we present information relating to the effectiveness and safety of the following intervention: optimum duration of maintenance drug treatment with serotonin reuptake inhibitors (SRIs) in children and adolescents.
据报道,导致个人痛苦或社会功能障碍的强迫观念或强迫行为影响约3%的儿童和青少年。在儿童中,该疾病通常在10岁左右出现。在平均5.7年的随访中,约40%的儿童和青少年的病情持续存在。该疾病会导致功能障碍,对包括教育和社会/家庭生活在内的功能产生不利影响。
我们进行了一项系统评价,旨在回答以下临床问题:儿童和青少年强迫症维持药物治疗的效果如何?我们检索了:截至2014年6月的Medline、Embase、Cochrane图书馆及其他重要数据库(临床证据综述会定期更新;请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品及保健品监管局(MHRA)等相关组织的危害警示。
纳入了两项涉及儿童和青少年强迫症维持药物治疗问题的研究。
在本系统评价中,我们提供了与以下干预措施的有效性和安全性相关的信息:儿童和青少年使用5-羟色胺再摄取抑制剂(SRIs)进行维持药物治疗的最佳持续时间。